Alpa Laboratories is a micro-cap, promoter-controlled Indian manufacturer of pharmaceutical finished dosage forms (FDFs) operating from a single WHO-GMP and ISO 9001-certified multi-dosage plant at Rau, near Indore. It produces injectables (liquid and dry-powder vials and ampoules), tablets, capsules, eye and ear drops, ointments, creams and gels for human use, and boluses, injections and intra-mammary infusions for veterinary use. It earns revenue through four channels: its own "Alpa" branded generics, a veterinary division, exports to emerging markets across Africa, Asia, Latin America and the CIS, and third-party contract manufacturing for domestic majors such as Cipla, Zydus, Lupin and Glenmark. With FY2026 revenue of about INR 106 Cr, virtually no debt and a treasury book of roughly INR 138 Cr that exceeds its market value, the company is better characterised as a cash-rich holding wrapped around a low-margin, sub-scale formulations business whose operating profitability has deteriorated sharply since FY2022.
---
### Company's own description
Across its annual reports and exchange profile, the company describes itself as a WHO-GMP and ISO 9001:2000 certified company that manufactures a wide range of pharmaceutical finished dosage forms under its own brand and for other Indian and multinational companies, with a product range spanning ethical, generic and over-the-counter (OTC) drugs for both human and veterinary use (Screener key points citing alpalabs.in; CRISIL rating rationale, August 2025). For financial reporting, the company treats its entire operation as a single business segment, "Drugs and Chemicals" (FY2023 annual report, as cited by Screener).
### What the company does
Alpa manufactures generic formulations in most conventional dosage forms at its Rau facility, which began commercial production in 1999 and has dedicated areas for liquid injections, dry injections, tablets, capsules, eye drops, ear drops, ointments, creams and gels (IIFL company summary; MarketsMojo company CV). Its therapeutic coverage, as summarised in investor-database descriptions derived from company materials, includes anti-infectives (antibacterials, antibiotics, antifungals, antiprotozoals, antivirals), analgesics and anti-inflammatories, cough and cold, cardiovascular, anti-diabetic, nutritional supplements, psychotropics, skin care, and ear and eye care (Investing.com profile).
### Business model and revenue model
| Division | Revenue model | Customer type |
|---|---|---|
| Branded Generic Division | Sale of own-brand products under the "Alpa" trademark through distributors, retail chemists, pharmacies and hospitals | Distributors, stockists, hospitals, retail pharmacies (India) |
| Veterinary Division | Sale of animal-health formulations (boluses, injections, intra-mammary infusions) | Veterinary distributors, dairy/livestock channel |
| Exports Division | Sale of formulations to importers and distributors in emerging markets, either under Alpa brands or partner brands | Overseas distributors, government/tender buyers (detail not disclosed) |
| Contract Manufacturing Division | Loan-licence / third-party manufacturing for other pharma companies' brands | Indian pharma companies including Cipla, Zydus Cadila, Lupin, Glenmark, Genom Biotech, Jenburkt |
The business is almost entirely product-based manufacturing revenue. There is no subscription or licensing revenue disclosed. Within product revenue, management historically organised marketing into four divisions (IIFL company summary):
Division-level revenue split: not publicly disclosed in sources accessed.
A material point for analysts: the "Alpa" trademark under which branded products are sold is registered in the name of Alpa Labs (India) Limited, a promoter-group company, not the listed entity (IIFL company summary). The listed company therefore does not own its principal brand asset, creating related-party dependency.
### Value-chain position
Alpa sits in the downstream formulation stage: it buys active pharmaceutical ingredients (APIs) and excipients, converts them into finished dosage forms, and sells either into its own distribution channel or to brand owners. It does not manufacture APIs and is not known to conduct original drug discovery. Its economic position is that of a price-taker in commoditised generic molecules (penicillins, albendazole, paracetamol, tinidazole, etc.) where competition is intense and margins are thin.
### Independent characterisation
The financial statements tell a story that differs materially from the "pharma manufacturer" label. In FY2025, other income (largely gains on investments) of INR 23.35 Cr was nearly five times operating EBITDA of INR 4.75 Cr (Anand Rathi, FY2025). In FY2026, other income of INR 15.76 Cr compared with operating EBITDA of INR 3.29 Cr. Consolidated investments and short-term securities rose from INR 70.3 Cr (FY2022) to INR 137.9 Cr (FY2026) (StockAnalysis balance sheet). The company has paid no dividend in at least a decade (Finanzen dividend calendar). In effect, the operating business generates modest cash that is accumulated in a growing treasury portfolio, and reported earnings are driven mainly by that portfolio's returns. In Q1 FY2027 (June 2026 quarter), the operating line turned negative (operating loss of INR 3.96 Cr), with other income of INR 5.77 Cr keeping the company profitable (Screener quarterly).
### End-markets served
India domestic generics (branded and trade generics); Indian animal health; emerging-market exports (Philippines, Iran, Iraq, Sierra Leone, Madagascar, Kenya, Liberia, Puerto Rico, Haiti, Sudan, Ghana, Nigeria, Sri Lanka per IIFL; also South and Central America, Africa, Asia and CIS countries including Russia, Ukraine and Kazakhstan per Investing.com and Stoxray profiles); and B2B contract manufacturing for Indian pharma majors.